Genesis Therapeutics
A Californian biotech company utilising AI to discover novel and breakthrough treatments for patients with severe and devastating conditions.
Genesis is using a proprietary generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and chemically aware language models.
In August 2023, Genesis closed an oversubscribed $200 million round of Series B financing.
Latest Genesis Therapeutics News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze